169 results on '"Abignano G"'
Search Results
2. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry 'SPRING' of the Italian Society for Rheumatology
3. POS1336 MRI DIGITAL ARTERY VOLUME INDEX (DAVIX©) AS QUANTITATIVE, CONTINUOUS IMAGING OUTCOME MEASURE OF VASCULAR DISEASE IN SYSTEMIC SCLEROSIS
4. POS0146 BIOSAMPLES FROM VEDOSS PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA:OPPORTUNITY FOR A BIOLOGICAL DIAGNOSIS OF DISEASE
5. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey
6. 404 Plaque Psoriasis patients with Psoriatic Arthritis demonstrate a reduced capacity to neutralise neutrophil derived elastase compared to plaque psoriasis patients without arthritis.
7. AB0142 EVIDENCE OF TYPE I INTERFERON ACTIVATION DURING VASCULAR MANIFESTATIONS OF SYSTEMIC SCLEROSIS
8. POS1267 LONG-TERM SURVEY STUDY OF THE IMPACT OF COVID-19 ON SYSTEMIC AUTOIMMUNE DISEASES. LOW DEATH RATE DESPITE THE INCREASED PREVALENCE OF SYMPTOMATIC INFECTION. ROLE OF PRE-EXISTING INTERSTITIAL LUNG DISEASE AND ONGOING TREATMENTS.
9. Use of optical coherence tomography for the diagnosis of preclinical lesions of circumscribed palmar hypokeratosis
10. Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
11. Retrospective comparison of drug treatment of joint involvement in systemic sclerosis: 6.18
12. OP0269 A COMBINED CLINICAL AND BIOMARKER ALGORITHM TO PREDICT FVC DECLINE IN SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM AN INTERNATIONAL MULTICENTRE OBSERVATIONAL COHORT
13. POS0319 PERFORMANCE OF PATIENT REPORTED OUTCOMES (PROs) IN SCLERODERMA PATIENTS WITH REDUCED LUNG FUNCTION IN AN OBSERVATIONAL COHORT
14. POS1246 COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY
15. Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma
16. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study
17. S.7.1 Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biological and radiographic findings
18. THU0342 DECLINE IN SUBCLINICAL SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT ASSOCIATES WITH POOR PROGNOSTIC FACTORS AND ACTIVE INTERSTITIAL LUNG DISEASE
19. SAT0321 CURRENT PATIENT REPORTED OUTCOMES (PROS) POORLY REFLECT CHANGES IN LUNG FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS
20. SAT0281 BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR DIAGNOSIS OF PRE-CLINICAL SSC
21. FRI0226 OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SYSTEMIC SCLEROSIS
22. THU0341 DIGITAL ARTERY VOLUME INDEX (DAVIX©) PREDICTS THE ONSET OF FUTURE DIGITAL ULCERS IN PATIENTS WITH SYSTEMIC SCLEROSIS
23. SAT0305 PERFORMANCE OF HIGH FREQUENCY ULTRASOUND IN THE ASSESSMENT OF SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS
24. AB0617 OPTICAL COHERENCE TOMOGRAPHY IN THE ASSESSMENT OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS: A CROSS-SECTIONAL STUDY
25. FRI0241 INFLUENCE OF PATIENT REPORTED ‘’ARTHRITIS ACTIVITY’’ IN DETERMINING SHAQ, HAQ-DI AND COCHIN SCORES IN SYSTEMIC SCLEROSIS
26. FRI0233 IMPACT AND ADHERENCE TO THE MEDITERRANEAN DIET IN SYSTEMIC SCLEROSIS ITALIAN PATIENTS: CORRELATION WITH GASTROINTESTINAL SYMPTOMS, MOOD DISTURBANCES AND QUALITY OF LIFE
27. A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: Data from the Leeds Combined Psoriatic Service
28. SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA
29. Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study.
30. Three‐dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis
31. FRI0328 Targeted therapy using intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE): first results from a proof-of-concept phase 2 trial
32. THU0393 The predictor of malnutrition in systemic sclerosis (PREMASS) score: a validated combined index predictive of future weight loss in systemic sclerosis
33. FRI0443 Digital artery volume index: the first objective, automated, non-invasive imaging diagnostic of macrovascular involvement in ssc
34. SAT0507 Implantable loop recorder can screen for incidental significant arrhythmias in scleroderma, with cardiac mri ecv and troponin biomarker, useful for risk stratification
35. THU0409 Management of systemic sclerosis (SSC) related digital ulcers (DU) in expert tertiary centres: results from the analysis of the multicentre observational real-life desscipher/eustar study
36. AB0029 Anti inflammatory effect of pde5 inhibition: scope for a new potential indication in ssc associated myositis
37. FRI0390 European multicentre study validates elf test as biomarker of fibrosis in systemic sclerosis
38. THU0659 Skin microvascular flow assessed by dynamic optical coherence tomography: first non-invasive quantitative outcome measure of microvascular damage in systemic sclerosis
39. FRI0370 Three-dimensional nailfold capillary imaging by dynamic optical coherence tomography in systemic sclerosis: a validation study using nailfold video-capillaroscopy
40. FRI0646 Three-dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis
41. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology
42. Three‐dimensional nail imaging by optical coherence tomography: a novel biomarker of response to therapy for nail disease in psoriasis and psoriatic arthritis.
43. ARTHRALGIAS ARE PREDICTIVE FACTORS OF FOOT INVOLVEMENT EVALUATED BY ULTRASONOGRAPHY IN PATIENTS WITH SYSTEMIC SCLEROSIS: A PROSPECTIVE STUDY
44. CROSS-SECTIONAL EVALUATION OF CHEMOKINE PROFILE IN EARLY AND DEFINITE SYSTEMIC SCLEROSIS
45. [OP0219] EUROPEAN SCLERODERMA STUDY GROUP (ESCSG) ACTIVITY INDEX IS CORRELATED TO QUALITY OF LIFE MEASURES BOTH AT ADMISSION AND OVERTIME M. Iudici, G. Cuomo, G. Abignano, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Objectives: EScSG activity index has been validated for construct validity [1]. Its discriminant validity awaits to be investigated. In order to address this aspect, we investigated the relationship between the activity index and Health Assessment Questionnaire-Disability Index, physical and mental component scores (PCS and MCS) of Short Form-36 (SF36). Methods: 140 SSc patients consecutively admitted at tertiary center were investigated for EScSG activity index, HAQ-DI and PCS and MCS of SF36 at enrolment and after 1 year. The change (Δ) for each of the all measures was calculated. Results: EScSG activity index was found to be correlated to HAQ-DI, PCS and MCS both at admission (Rho=0.49, p=0.0003; Rho= -0.40, p<0.0001; Rho= -0.29, p=0.001, respectively) and after 1 year (Rho=0,64, p<0,0001; Rho= -0.29, p=0.001; Rho=-0.18, p=0.046 respectively). Moreover, the change between the value of the activity index at 1 year and that at admission (Δ activity index) was significantly correlated to ΔHAQ-DI, ΔPCS, ΔMCS (Rho=0,43, p=0.002; Rho=0,56, p<0.0001; Rho=0.48, p=0.002, respectively). Conclusion: HAQ-DI and SF36 (PCS and MCS) are considered to be validated outcome measure in SSc. Our results further support the construct validity of EScSG activity index and are for the first time underline its discriminant validity. References: • Valentini G. et al. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003. Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):128 Session: Abstract Session: Modern prespective in systemic sclerosis
46. [THU0309] CLINICAL MANIFESTATIONS IN LATE VS EARLY –ONSET SYSTEMIC SCLEROSIS (SSC) G. Cuomo, M. Iudici, G. Abignano, G. Valentini. Second Universty of Naples, Rheumatology Unit, Naples, Italy Background: Differences have been so far pointed out in the clinical manifestations and disease course in patients with a number of autoimmune rheumatic diseases and different age at onset (1-3). Objectives: To investigate the occurrence of differences between early and late onset SSc. Methods: 260 SSc patients (233 females) with a median age at the onset of the disease of 40.5 years (range 8-74) were consecutively admitted to a tertiary centre from November 1st 2000 to October 31st 2008. They were divided into 2 groups: early onset (<40.5 years) and late onset (≥40.5 years). Differences in each of the epidemiological, clinical and serological aspects collected in all the patients at admission were analysed. Results: Table 1 lists the significant differences detected between the 2 groups. Early onset patients were found to have a longer disease duration at presentation, a higher prevalence of anti-Scl70 positivity and a higher prevalence of scleroderma renal crisis; a lower prevalence of antinucleolar antibody positivity; a lower percentage of pulmonary hypertension; a lower HAQ-DI and a lower prevalence of heart involvement. No difference was detected in clinical subset distribution. Late onset (138) Early onset (122) p Disease duration mean (sd) 6 (6) 10 (10) 0.003 Range (median) 0.5-26 (5) 0.5-45 (6) Serological subset Scl70 43 54 0.04 Nucleolar 9 23 0.004 PAPs ≥40mmHG (echocardiography) 14/124 3/119 0.01 HAQ-DI mean (sd) 0.65 (0.7) 0.5 (0.7) 0.037 Range (median) 0-0.275 (0.375) 0-0.25 (0.125) Severity scale Late onset (138) Early onset(122) p 0-1 2-3-4 0-1 2-3-4 Heart 117 21 121 1 <0.0001 Kidney 138 0 117 5 0.02 Conclusion: Our study demonstrate that similarly to systemic lupus erithematosus and rheumatoid arthritis, distinct differences related to age at onset also occur in SSc patients. References: • Calvo-Alen J. et al, Clin Rheumatol 2005 • Lalani S. et al, J Rheumatol 2010 • Ho CT et al, Ann Rheum 1998 Disclosure of Interest: None declared Citation: Ann Rheum Dis 2010;69(Suppl3):247 Session: Scleroderma, Myositis and related syndromes
47. TWENTYFOUR-MONTH AZATHIOPRINE AS MAINTENANCE THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE TREATED WITH LOW DOSE CYCLOPHOSPHAMIDE PULSE THERAPY
48. [FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes
49. ARTICULAR INVOLVEMENT IN SYSTEMIC SCLEROSIS (SSC). ULTRASONOGRAPHIC FEATURES OF HAND JOINTS
50. [FRI0311] CORRELATIONS BETWEEN CLINICAL FEATURES OF154 PATIENTS WITH SYSTEMIC SCLEROSIS (SSC) AND SHORT FORM36 (SF36) SCORES G. Cuomo, M. Iudici, G. Abignano, A. Petrillo, G. Valentini. Rheumatology Unit, Second University of Naples, Naples, Italy Background: The quality of life is reduced in patients with systemic sclerosis (SSc) as evaluated by both disease specific (HAQ-DI; SHAQ) or generic questionnaires. The correlations between SF-36 scores and some disease features have not yet been explored. Objectives: To evaluate the relationships between health values as evaluated by SF-36 and clinical features in SSc patients. Methods: From 9/01/07 to 8/31/08 154 consecutive SSc patients (144 females; 10 males); aged from 20–82 years (median age 54), with disease duration from 1-47 years (median 10,5 years); attending the outpatient clinic of the Rheumatology Unit of Second University of Naples, were enrolled in the study. The scores of the eight areas of SF-36 General Health: Physical Function (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social function (SF), Role Emotional (RE) and Mental Health (MH), were evaluated in the range of 0–100, the higher values reflecting a better Quality of life (Qol). In addition two global series i.e. the Physical Component Summary Score (PCS) and the Mental Component Summary Score (MCS) were calculated. The patients were also investigated for disease subset (limited or diffuse); skin involvement by the modified Rodnan skin score; disability by HAQ-DI; disease activity by European Activity Index, and disease severity by Medsger severity scale. Results: SF36 score did not differ between the 31 patients with diffuse vs the 123 with limited disease All the items of SF36 were significantly correlated to activity Index (Rho from –0.28 to -0.32: p<0.0001) and HAQ-DI (Rho from -0.38 to -0.82: p<0.0001). GH resulted to correlate with mRss (Rho -0.17; p<0.05) The significant correlations between each item of the Medsger's severity scale and each item of SF36 are reported in table. PF RP BP GH VT SF RE MH PCS/MCS Sev_Gen (Rho) – – – – – – – – –/– Sev_Vasc(Rho) – – – – – – – – –/– Sev_Skin (Rho) – – – – – – – – –/– Sev_Joint (Rho) – – – -0.18* – – – – -0.21**/– Sev_muscle (Rho) -0.25** – – -0.16* -0.18* -0.22* – -0.20* -0.20*/– Sev_GI (Rho) -0.20* – – -0.22** – – – – –/– Sev_lung (Rho) -0.28*** – – -0.23** -0.17* -0.23** -0.22** – -0.19*/– Sev_Heart (Rho) – – -0.22* – – – – – -0.21*/– Sev_kidney (Rho) – – – – – – – – – *p<0.05; **p<0.001; ***p<0.0001. Conclusion: The present study, confirms that the Health Value, as evaluated by SF36, is diminished in SSc. Our study point out a previously univestigated correlation between SF-36 scores and disease activity. Disclosure of Interest: NONE declared Ann Rheum Dis 2009;68(Suppl3):459 Session: Scleroderma, myositis and related syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.